NEUROMETRIX, INC. (NASDAQ:NURO) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07
|
Submission of Matters to a Vote of Security Holders
|
stockholders (the Special Meeting) at the offices of Mintz,
Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial
Center, Boston, MA 02111 on February 28, 2017. Of the Companys
7,114,901 shares of common stock issued and outstanding and
eligible to vote as of the record date of January 9, 2017, a
quorum of 5,806,748 shares, or 81.6% of the eligible shares, was
present in person or represented by proxy. Each of the matters
set forth below is described in detail in the definitive proxy
statement filed with the Securities and Exchange Commission on
January 23, 2017. The following actions were taken at the Special
Meeting:
|
1.
|
Approval of the issuance of shares of the Companys Series E
convertible preferred stock and warrants to purchase shares of its common stock to an institutional investor and its affiliates (the Investor) to the Securities Purchase Agreement, dated as of December 28, 2016, by and between the Corporation and the Investor (the Securities Purchase Agreement) and to approve the other transactions contemplated thereby, including the resetting of the exercise prices of warrants to purchase shares of the Company’s common stock, to comply with NASDAQ Marketplace Rule 5635(d): |
|
Votes For
|
|
Votes Against
|
|
Votes Abstained
|
|
|
Broker Non-Votes
|
|
|
2,823,278
|
|
257,058
|
|
8,044
|
|
|
2,718,368
|
|
|
2.
|
Approval of the resetting of the conversion price of the
Companys Series D convertible preferred stock held by the Investor, as required by the Securities Purchase Agreement: |
|
Votes For
|
|
Votes Against
|
|
Votes Abstained
|
|
|
Broker Non-Votes
|
|
|
2,823,278
|
|
257,058
|
|
8,044
|
|
|
2,718,368
|
|
|
3.
|
Approval of an amendment to the Companys Third Amended and
Restated Certificate of Incorporation to increase the number of shares of the Companys common stock authorized for issuance from 100,000,000 shares to 150,000,000 shares: |
|
Votes For
|
|
Votes Against
|
|
Votes Abstained
|
|
|
|
4,269,209
|
|
1,514,162
|
|
23,377
|
|
|
|
4.
|
Authorization to adjourn the Special Meeting, if necessary,
if a quorum is present, to solicit additional proxies if there are not sufficient votes in favor of Proposals 1, 2 and 3: |
|
Votes For
|
|
Votes Against
|
|
Votes Abstained
|
|
|
|
4,543,021
|
|
1,180,487
|
|
83,240
|
|
|
because there were sufficient votes in favor of Proposals 1, 2 and
3.>>
About NEUROMETRIX, INC. (NASDAQ:NURO)
NeuroMetrix, Inc. (NeuroMetrix) is a health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians manage chronic pain, nerve diseases and sleep disorders. The Company operates through the sale of medical equipment and consumables segment. Its products are sold in the United States and selected overseas markets. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The Company’s products consist of a medical device used in conjunction with a consumable electrode or biosensor. Its products include Quell, which is a wearable device for relief of chronic intractable pain; SENSUS, which is a prescription neuro-stimulation device; DPNCheck, which is a nerve conduction test that is used to evaluate systemic neuropathies, and ADVANCE System, which is a platform for the performance of nerve conduction studies. NEUROMETRIX, INC. (NASDAQ:NURO) Recent Trading Information
NEUROMETRIX, INC. (NASDAQ:NURO) closed its last trading session down -0.034 at 0.605 with 52,578 shares trading hands.
